TY - JOUR
T1 - Understanding opioid overdose characteristics involving prescription and illicit opioids
T2 - A mixed methods analysis
AU - Yarborough, Bobbi Jo H.
AU - Stumbo, Scott P.
AU - Janoff, Shannon L.
AU - Yarborough, Micah T.
AU - McCarty, Dennis
AU - Chilcoat, Howard D.
AU - Coplan, Paul M.
AU - Green, Carla A.
N1 - Funding Information:
Drs. Chilcoat and Coplan are employees of Purdue Pharma LP and, as such, are members of the Industry PMR Consortium, a consortium of 10 companies working together to conduct FDA-required post-marketing studies that assess known risks related to extended-release, long-acting opioid analgesics. The Industry PMR consortium is comprised of Pfizer, Purdue Pharma, Roxane Laboratories, Janssen Pharmaceuticals, Mallinckrodt, Actavis, Endo Pharmaceuticals, Depomed and Pernix. All of the remaining authors received grant support from Purdue Pharma LP and currently receive grant support from the Industry PMR Consortium. Dr. Green has also provided research consultation for the Industry PMR. Drs. Yarborough, McCarty, and Green, Mr. Stumbo, and Mr. Yarborough receive grant support from NIMH. Drs. Yarborough, McCarty, and Green, Ms. Janoff, Mr. Stumbo and Mr. Yarborough receive grant support from NIDA. Mr. Stumbo receives grant support from the Maternal and Child Health Bureau and Autism Speaks. Dr. McCarty was PI on Research Service Agreements from Purdue Pharma LP and Alkermes.
Funding Information:
This study was funded by Purdue Pharma, L.P. as part of post-marketing requirements by the Food & Drug Administration to examine opioid overdose risks. We would like to thank Alison Firemark for her work conducting interviews, Thomas Young for his help coding transcripts, and Kevin Lutz for his editorial assistance. Finally, we would like to thank the individuals and family members who participated in this study.
Funding Information:
This project was conducted as part of the study “Overdose Rates Among Patients Prescribed OxyContin ® , Comparator Opioids, and No Opioids in the Kaiser Permanente Northwest & Kaiser Permanente Northern California Health Systems” which was funded by Purdue Pharma, L.P. The study was funded as part of post-marketing requirements by the Food & Drug Administration (FDA) to examine opioid overdose risks. Under Food & Drug Administration (FDA) direction and approval, the funder was involved in the overall study design. The funder had no role in the analysis or interpretation of the results; however they did review and comment on previous drafts and the final version of the manuscript. The funder was not involved in the decision of where to submit the paper for publication.
Publisher Copyright:
© 2016 Elsevier Ireland Ltd
PY - 2015/11/23
Y1 - 2015/11/23
N2 - Background Opioid abuse and misuse are significant public health issues. The CDC estimated 72% of pharmaceutical-related overdose deaths in the US in 2012 involved opioids. While studies of opioid overdoses have identified sociodemographic characteristics, agents used, administration routes, and medication sources associated with overdoses, we know less about the context and life circumstances of the people who experience these events. Methods We analyzed interviews (n = 87) with survivors of opioid overdoses or family members of decedents. Individuals experiencing overdoses were members of a large integrated health system. Using ICD codes for opioid overdoses and poisonings, we identified participants from five purposefully derived pools of health-plan members who had: 1) prescriptions for OxyContin® or single-ingredient sustained-release oxycodone, 2) oxycodone single-ingredient immediate release, 3) other long-acting opioids, 4) other short-acting opioids, or 5) no active opioid prescriptions. Results Individuals who experienced opioid overdoses abused and misused multiple medications/drugs; experienced dose-related miscommunications or medication-taking errors; had mental health and/or substance use conditions; reported chronic pain; or had unstable resources or family/social support. Many had combinations of these risks. Most events involved polysubstance use, often including benzodiazepines. Accidental overdoses were commonly the result of abuse or misuse, some in response to inadequately treated chronic pain or, less commonly, medication-related mistakes. Suicide attempts were frequently triggered by consecutive negative life events. Conclusions To identify people at greater risk of opioid overdose, efforts should focus on screening for prescribed and illicit polysubstance use, impaired cognition, and changes in life circumstances, psychosocial risks/supports, and pain control.
AB - Background Opioid abuse and misuse are significant public health issues. The CDC estimated 72% of pharmaceutical-related overdose deaths in the US in 2012 involved opioids. While studies of opioid overdoses have identified sociodemographic characteristics, agents used, administration routes, and medication sources associated with overdoses, we know less about the context and life circumstances of the people who experience these events. Methods We analyzed interviews (n = 87) with survivors of opioid overdoses or family members of decedents. Individuals experiencing overdoses were members of a large integrated health system. Using ICD codes for opioid overdoses and poisonings, we identified participants from five purposefully derived pools of health-plan members who had: 1) prescriptions for OxyContin® or single-ingredient sustained-release oxycodone, 2) oxycodone single-ingredient immediate release, 3) other long-acting opioids, 4) other short-acting opioids, or 5) no active opioid prescriptions. Results Individuals who experienced opioid overdoses abused and misused multiple medications/drugs; experienced dose-related miscommunications or medication-taking errors; had mental health and/or substance use conditions; reported chronic pain; or had unstable resources or family/social support. Many had combinations of these risks. Most events involved polysubstance use, often including benzodiazepines. Accidental overdoses were commonly the result of abuse or misuse, some in response to inadequately treated chronic pain or, less commonly, medication-related mistakes. Suicide attempts were frequently triggered by consecutive negative life events. Conclusions To identify people at greater risk of opioid overdose, efforts should focus on screening for prescribed and illicit polysubstance use, impaired cognition, and changes in life circumstances, psychosocial risks/supports, and pain control.
KW - Intervention
KW - Opioid analgesics
KW - Overdose
KW - Prevention
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=84994236203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994236203&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2016.07.024
DO - 10.1016/j.drugalcdep.2016.07.024
M3 - Article
C2 - 27520885
AN - SCOPUS:84994236203
SN - 0376-8716
VL - 167
SP - 49
EP - 56
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
ER -